# US 2001/0034369 A1 · Integrin antagonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0034369 A1
- Document ID: US20010034369A1
- Status: Published application
- Kind: A1
- Application number: 09/855,448
- Filed: 2001-05-15
- Published: 2001-10-25
- Earliest claimed: 1996-12-09
- Assignees: Eli Lilly and Company
- Inventors: Robert M. Scarborough; Mark Smyth; Ting Su; Matthew J. Fisher; Joseph A. Jakubowski; John J. Masters; Jeffry Bernard Franciskovich
- Web page: https://patentgrep.com/patent/US20010034369A1

## CPC

- C07D 211/62: attached in position 4
- C07C 311/06: to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
- C07C 311/19: to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C 2601/14: The ring being saturated
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

Novel compounds, their salts and compositions related thereto having activity against mammalian integrins are disclosed. The compounds are useful in vitro or in vivo for preventing or treating thrombotic or restenotic disorders.

## Claims

### Claim 1

A compound having the formula:
45
wherein:
Y is selected from the group consisting of —COOH and —COOR4; where R4 is selected from the group consisting of C1-10alkyl, C1-8alkylaryl, and aryl-C1-8alkyl;
A is selected from the group consisting of C0-8alkyl-NR5—CO—C0-8alkyl, C0-8alkyl-CO—NR5-C0-8alkyl, C0-8alkyl-NR5 —CO—C1-8alkyl-NR5 —CO—C0-8alkyl, C0-8alkyl-CO—NR5—DC1-8alkyl-NR5—CO—C0-8alkyl, C0-8alkyl-CO—NR5—C0-8alkyl-CO—NR5—C0-8alkyl, C0-8alkyl-CO—C1-8aIkyl—CO—NR5—C0-8alkyl, C0-8alkyl-NR5—C0-8alkyl-CO—NR5—C0-8alkyl, C0-8alkyl-O—C0-8alkyl-CO—NR5—C0-8alkyl, and C0-8alkyl-O—C2-8alkyl-O—C0-8alkyl-CO—NR5—C0-8alkyl; where R5 are independently selected from the group consisting of H and C1-6alkyl;
Z is selected from the group consisting of —NH—C(NR9R10)═NR11 and —C(NR9R10)═NR; where R9, R10 and R11 are independently selected from the group consisting of H and C1-6alkyl;
R1 is H;
R2 is selected from the group consisting of —SOm-aryl and —SOm—C1-10alkyl, where m=2; and
R3 is H;
and all pharmaceutically-acceptable stereoisomers, salts, hydrates, solvates and prodrug derivatives thereof.

### Claim 2 (depends on 1)

The compound of claim 1 wherein Y is —COOH.

### Claim 3 (depends on 1)

The compound of claim 1 wherein R2 is —SO2-aryl.

### Claim 4 (depends on 1)

The compound of claim 1 wherein R4 is C1-10alkyl.

### Claim 5 (depends on 1)

The compound of claim 1 wherein R9, R10 and R11 are H.

### Claim 6 (depends on 1)

The compound of claim 1 wherein Z is —NH—C(NR9R10)═NR11.

### Claim 7 (depends on 1)

The compound of claim 1 wherein A is selected from the group consisting of C0-8alkyl-NR5—CO—C0-8alkyl, C0-8alkyl-NR5—CO—C1-8alkyl-NR5—CO—C0-8-alkyl, C0-8alkyl-CO—C1-8alkyl-CO—NR5—C0-8alkyl, and C0-8alkyl-O—C0-8alkyl-CO—NR5-C0-8alkyl.

### Claim 8 (depends on 7)

The compound of claim 7 wherein Y is —COOH; Z is —NH— C(NR9R10)═NR11; R9, R10 and R11 are H; and R2 is —SO2-aryl.

### Claim 9 (depends on 1)

The compound of claim 1 wherein A is selected from the group consisting of C0-8alkyl-NR5 —CO—C1-8alkyl-NR5 —CO—C0-8alkyl, and C0-8alkyl-O—C0-8alkyl-CO—NR5 —C0-8alkyl.

### Claim 10 (depends on 9)

The compound of claim 9 wherein Y is —COOH; Z is —NH—C(NR9R10)═NR11; R9, R10 and R11 are H; and R2 is —SO2-aryl.

### Claim 11 (depends on 1)

The compound of claim 1, having an IC50 of less than about 200 nM.

### Claim 12 (depends on 1)

A compound of claim 1 selected from the group consisting of:
46

### Claim 13 (depends on 1)

A pharmaceutical composition for preventing or treating a condition in a mammal characterized by undesired thrombosis comprising a therapeutically-acceptable carrier and a therapeutically-effective amount of a compound of claim 1.

### Claim 14 (depends on 1)

A method for preventing or treating a condition in a mammal characterized by undesired thrombosis comprising administering to said mammal a therapeutically-effective amount of a compound of claim 1.

### Claim 15 (depends on 14)

The method of claim 14, wherein the condition is selected from the group consisting of: acute coronary syndrome, myocardial infarction, unstable angina, refractory angina, occlusive coronary thrombus occurring post-thrombolytic therapy or post-coronary angioplasty, a thrombotically mediated cerebrovascular syndrome, embolic stroke, thrombotic stroke, transient ischemic attacks, deep venous thrombosis, pulmonary embolus, coagulopathy, disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, thromboangiitis obliterans, thrombotic disease associated with heparin-induced thrombocytopenia, thrombotic complications associated with extracorporeal circulation, thrombotic complications associated with instrumentation such as cardiac or other intravascular catheterization, intra-aortic balloon pump, coronary stent or cardiac valve, conditions requiring the fitting of prosthetic devices, vascularization of solid tumors and retinopathy.

### Claim 16

A compound selected from the group consisting of:
47

### Claim 17

A compound selected from the group consisting of:
48
or a pharmaceutically acceptable stereoisomer, salt, solvate, hydrate, or prodrug derivative thereof.

### Claim 18 (depends on 17)

A compound of claim 17, selected from the group consisting of:
49

### Claim 19 (depends on 17)

A compound of claim 17, selected from the group consisting of:
50

### Claim 20 (depends on 17)

A compound of claim 17, selected from the group consisting of:
51

### Claim 21 (depends on 17)

A pharmaceutical composition for preventing or treating a condition in a mammal characterized by undesired thrombosis comprising a therapeutically-acceptable carrier and a therapeutically-effective amount of a compound of claim 17.

### Claim 22 (depends on 17)

A method for preventing or treating a condition in a mammal characterized by undesired thrombosis comprising administering to said mammal a therapeutically-effective amount of a compound of claim 17.

### Claim 23 (depends on 22)

The method of claim 22, wherein the condition is selected from the group consisting of: acute coronary syndrome, myocardial infarction, unstable angina, refractory angina, occlusive coronary thrombus occurring post-thrombolytic therapy or post-coronary angioplasty, a thrombotically mediated cerebrovascular syndrome, embolic stroke, thrombotic stroke, transient ischemic attacks, deep venous thrombosis, pulmonary embolus, coagulopathy, disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, thromboangiitis obliterans, thrombotic disease associated with heparin-induced thrombocytopenia, thrombotic complications associated with extracorporeal circulation, thrombotic complications associated with instrumentation such as cardiac or other intravascular catheterization, intra-aortic balloon pump, coronary stent or cardiac valve, conditions requiring the fitting of prosthetic devices, vascularization of solid tumors and retinopathy.
